查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864308

馬匹保健市場按產品類型、最終用戶、疾病和給藥途徑分類－2025-2032年全球預測

Equine Healthcare Market by Product Type, End User, Disease Indication, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，馬匹保健市場將成長至 58.3 億美元，複合年成長率為 6.73%。

關鍵市場統計數據
基準年 2024 34.6億美元
預計年份：2025年 37億美元
預測年份 2032 58.3億美元
複合年成長率 (%) 6.73%

一套權威的當代馬匹健康照護優先事項框架，強調預防、診斷整合和協作式臨床創新。

馬匹醫療保健領域正在經歷一場變革。臨床需求、馬主期望和技術發展趨勢的交匯，正在重塑醫療保健服務和產品開發的優先事項。人們越來越重視預防和健康維護，並且更加關注能夠早期發現疾病的診斷技術，以及支持馬匹長期運動能力和生活品質的治療方法。因此，從臨床醫生到馬主，相關人員都在調整他們的診療實踐和籌資策略，以體現更積極主動的馬匹醫療保健管理模式。

從被動治療模式轉向預防性護理模式的轉變，需要建立新的工作流程，增加對監測和診斷技術的投資，並加強獸醫、研發機構和產品開發人員之間的合作。這項轉變的驅動力在於人們對治療效果的期望不斷提高，對循證干預措施的需求日益成長，以及能夠實現遠端監測和數據驅動決策的數位化工具的普及。因此，該領域的機構必須將傳統的臨床方法與創新技術結合，以期提高檢測率，標靶治療，並顯著改善動物福利。

鑑於這些趨勢，策略舉措應強調臨床、商業和馬主等相關利益者之間的合作。明確的目標以及務實的試點和推廣新技術的路徑將決定哪些創新能夠成功。最終，馬匹醫療保健領域正朝著更整合、數據主導的模式發展，該模式強調合作、嚴格檢驗以及對動物長期福利的明確關注。

技術進步、不斷變化的照護模式以及馬主的期望如何融合，重新定義馬匹醫療保健服務和產品創新？

在科技的日趨成熟、疾病管理理念的演變以及相關人員行為的改變的推動下，馬匹醫療保健領域正經歷著一場變革。先進的影像技術和照護現場技術正在降低診斷的不確定性，縮短干預時間；而穿戴式監測平台則能夠實現持續的數據收集，並支持制定個人化的護理方案。同時，治療方法也不斷多樣化，標靶藥物和旨在促進康復和提升運動表現的專用飼料補充劑的出現，拓展了臨床醫生和馬主可選擇的治療途徑。

遠端醫療、遠端監測和基於訂閱的健康計劃。這些運作方式的改變促使寵物主人對透明度、便利性和可衡量的結果提出更高的要求，從而加速了能夠提供即時資訊和顯著益處的服務的普及。研究機構也積極回應，優先進行轉化研究，以檢驗診斷工具和治療方法，從而在臨床實踐和科學研究之間建立起回饋機制。

此外，監管思維和供應鏈韌性正在影響產品策略，促使製造商投資配方穩定性、低溫運輸物流和簡化給藥途徑。這些趨勢並非孤立存在，而是相互促進，共同建構了一個互聯互通、靈活敏捷的生態系統，在這個系統中，那些展現價值和易用性的創新最有可能實現規模化發展。

評估近期貿易政策變化對馬匹醫療保健產業採購、供應和物流優先事項的重塑及其對營運和供應鏈的影響。

美國近期關稅調整為馬匹醫療保健產業的供應鏈、籌資策略和產品生命週期規劃帶來了許多複雜影響。進口零件和成品關稅的提高迫使製造商和經銷商重新評估供應商關係，盡可能優先考慮在地採購，並調整物流結構以維持利潤率和供應的連續性。這些調整對醫療設備、診斷設備和某些藥品的供應、前置作業時間和成本結構都產生了實際的影響。

為此，許多相關人員正在尋求採購多元化策略，以降低依賴單一供應商的風險。製造商正在探索替代生產基地和雙重採購安排，而經銷商和大型獸醫診所則在加強庫存計劃和安全庫存政策，以應對交貨週期的波動。同時，契約製造和國內供應商也發現，客戶對可靠的跨境運輸替代方案的需求日益成長，這促使業界重新評估議價動態和生產力計畫。

在採購決策中，監管合規性和標籤要求的重要性日益凸顯，因為產品在複雜的海關系統中流動時可能面臨額外的審查和延誤。因此，採購部門正在投入更多資源用於海關專業知識和供應商審核，而研究機構和臨床醫生則優先考慮那些供應鏈韌性已得到驗證的產品。這些因素共同造就了一個在不斷變化的貿易政策面前，更加重視透明度、冗餘性和靈活性的市場。

全面的細分分析，將產品類型、最終用戶、疾病適應症和給藥途徑映射到策略創新和商業化路徑。

有效的細分框架能夠揭示產品類型、最終用戶、疾病適應症和給藥途徑等因素交匯處的創新與需求，從而提供有針對性的開發和商業化藍圖。就產品類型而言，市場涵蓋醫療設備、診斷試劑、飼料添加劑、藥品和疫苗。在醫療設備領域，存在著許多機遇，例如支持持續評估的監測設備、用於治療骨骼和關節疾病的整形外科器械以及能夠實現高級手術干預的外科器械。在診斷試劑領域，存在著許多機遇，例如成像技術、實驗室分析方法以及能夠支援臨床現場快速決策的照護現場技術。飼料添加劑分為礦物質、營養素和維生素製劑，旨在支持系統健康和恢復。藥品包括抗發炎藥、抗寄生蟲藥、抗生素和荷爾蒙。在抗發炎藥物中，皮質類固醇和非類固醇消炎劑(NSAIDs) 是主要的治療選擇，而抗寄生蟲藥則分為體外寄生蟲藥和體內寄生蟲藥。與馬匹照護相關的抗生素類別包括BETA-內醯胺類、大環內酯類和四環黴素。激素分為生長促進劑和生殖促進劑。疫苗有去活化疫苗、減毒活病毒疫苗和重組疫苗三種形式，每種疫苗的儲存和給藥方式都有其獨特的注意事項。

從終端用戶的觀點來看，該生態系統由馬主、線上藥局、研究機構和獸醫診所組成。馬主分為養殖場和個別馬主，其管理規模和預防保健的投資重點各不相同。線上藥局透過非處方藥和處方藥管道營運，提供便利和豐富的選擇，但也需要謹慎的臨床管理。研究機構的特點是既有促進創新和檢驗的公立機構，也有私立機構；獸醫診所則涵蓋大型綜合動物醫院和專注於個人化護理的私人診所。疾病適應症的細分同樣突顯了臨床需求和產品相關性：胃腸道疾病，如腹痛、腹瀉和潰瘍，需要快速診斷和支持治療；感染疾病，分為細菌性、寄生蟲性和病毒性，需要綜合的預防和治療策略；肌肉骨骼疾病，包括關節疾病、整形外科損傷和軟組織損傷，則受益於康復和藥物治療相結合的方法。子宮內膜炎和不孕症等生殖系統疾病需要相應的治療和診斷方案。呼吸系統疾病分為下呼吸道疾病和上呼吸道疾病，每種疾病都需要特定的給藥途徑和支持性照護方案。

考慮給藥途徑有助於了解吸入、注射、口服和外用等不同給藥途徑的研發和應用趨勢。吸入途徑包括乾粉吸入和霧化吸入，兩者均適用於標靶呼吸系統介入。注射途徑包括肌肉注射、靜脈注射和皮下注射，這些途徑會影響起效時間和給藥策略。口服途徑包括液體、粉末和片劑，其主要特點是便於居家照護。外用療法，包括乳膏、凝膠和噴霧劑，可實現局部治療，同時最大限度地減少全身暴露。對這些細分維度的全面了解，有助於研發人員和臨床醫生更好地確定投資優先級，並根據每個用戶群體和適應症的具體需求和限制客製化產品。

區域差異和戰略機會（美洲、歐洲、中東和非洲、亞太地區）對打入市場策略和研發優先事項具有重要意義。

區域趨勢影響投資領域、研究重點和應用方向。了解這些差異對於市場准入和夥伴關係決策至關重要。在美洲，先進的臨床基礎設施、積極的飼主參與以及對伴侶動物和競技馬匹的重視，共同推動了對先進診斷技術、專業治療方法和綜合護理模式的需求。該地區優先考慮循證治療方法，並率先採用遠距監測和遠端保健服務，從而在某些領域推動了醫療保健的優質化。

儘管歐洲、中東和非洲地區（EMEA）的法規環境和獸醫實踐規範存在顯著差異，但該地區正朝著統一的護理標準穩步邁進，尤其是在感染疾病監測和疫苗策略方面。該地區部分地區的公私合營和強大的研究網路正在促進多中心合作和轉化研究，而其他市場則更注重成本效益高的配方和適用於不同實踐環境的實用通訊協定。

亞太地區正經歷臨床快速現代化、中產階級擁有運動和休閒馬匹人數不斷成長以及對本地生產能力日益重視等多重挑戰。整個地區不斷成長的需求往往推動著對國內研發和生產的定向投資，同時法律規範也在不斷改進，以適應更廣泛的診斷和治療產品。整體而言，每個區域叢集都面臨獨特的機會和挑戰，優先制定能夠兼顧臨床實踐模式、法律規範和當地供應鏈實際情況的區域策略，將帶來最永續的成果。

競爭評估著重於證據產生、供應鏈敏捷性和策略夥伴關係關係，以推動差異化和市場接受度。

馬匹醫療保健領域的競爭格局由成熟的動物用藥品製造商、專業醫療器材和診斷公司、獸醫分銷網路以及專注於小眾療法和數位監測的敏捷型新興企業組成。現有企業往往在多個產品類型中維持業務佈局，利用規模經濟、監管經驗和廣泛的分銷網路。同時，專業公司憑藉著深厚的臨床洞察力、專業的科技平台以及與獸醫的緊密合作，獲得競爭優勢。新參與企業則可望透過數位化工具、照護現場診斷和配方創新，降低使用門檻並提高飼主參與度，從而顛覆現有格局。

設備製造商與診斷開發商之間的合作日益增多，從而能夠提供集監測、數據分析和治療建議於一體的綜合解決方案。此外，產學合作正在加速轉化研究，以檢驗新型治療方法在臨床環境中的有效性。通路也至關重要，線上藥局和專業獸藥經銷商影響著產品的認知度和可及性，而大型動物醫院和獨立診所則基於產品在實際應用中的表現以及與臨床工作流程的整合便捷性，影響著臨床應用。

智慧財產權、監管經驗和生產彈性是企業競爭優勢的關鍵。能夠提供經證實的臨床療效、高效管理以及對醫療專業人員的強力支持的企業更有可能獲得市場優勢。最終，在複雜且以臨床主導的市場中，那些注重證據產生、供應鏈可靠性和客製化商業性合作的企業策略最有可能取得成功。

切實可行的策略性舉措，旨在幫助產業領導者增強韌性、進行創新臨床檢驗，並透過整合的商業性模式加速產品應用。

產業領導者應優先考慮一系列切實可行的措施，以平衡短期營運韌性與長期創新和實證研究。首先，他們需要投資供應鏈的透明度和冗餘性，以減輕貿易政策變化和零件短缺對營運的影響。與多家合格供應商建立合作關係並加強物流規劃，可以在維持品質標準的同時降低中斷風險。

第二，加速結合診斷和治療的臨床檢驗項目，以展示真實世界的臨床療效。進行涉及獸醫診所和研究機構的嚴謹轉化研究，有助於建立醫療專業人員的信任，並促進技術的廣泛應用。第三，透過實施監測平台和遠端醫療工作流程，促進數位整合。這將提高醫療服務的連續性，並透過數據驅動的洞見創造價值。這些工具的設計應確保與現有臨床系統無縫整合，並易於使用。

第四，透過認知到養殖場和個別養殖戶之間的差異，並制定優先考慮合規性和實用性的通路策略，從而調整商業性策略以適應不同的終端用戶群體。第五，探索策略聯盟，將醫療設備、診斷和製藥領域的互補優勢結合起來，以提供貫穿臨床路徑的綜合解決方案。最後，追求卓越的監管事務和合規性，以確保加快核准和持續的市場進入。這些努力共同構成了一條切實可行的藍圖，既能推動業務永續營運，又能產生臨床影響。

本報告採用嚴謹的多方法研究框架，整合了關鍵相關人員的見解、監管審查和跨細分市場分析，從而得出可操作的結論。

本報告的研究融合了多種定性和定量方法，以確保得出可靠且可操作的見解。主要研究包括對獸醫、實驗室技術人員、行業高管和馬主進行結構化訪談，以收集關於臨床需求、推廣障礙和產品性能的不同觀點。次要研究則查閱了同行評審文獻、監管指南、技術標準和公共文件，以建立基於檢驗資訊來源的觀察結果，並分析區域差異。

分析採用交叉細分映射法，識別產品類型、最終用戶、疾病適應症和給藥途徑與未滿足需求交叉的領域。供應鏈和貿易政策分析利用海關數據、物流績效指標和官方貿易通報來評估營運脆弱性。競爭格局分析結合專利申請、產品註冊資訊和臨床試驗註冊資訊，評估創新路徑和差異化策略。在整個研究過程中，方法論強調證據三角驗證、迭代同儕檢驗以及對區域監管和實踐差異的考慮。

這種多層次的調查方法確保結論有觀察到的實踐和已記錄的證據支持，同時又能對新興趨勢保持敏銳的洞察力。在原始資料有限的情況下，研究結果會受到質疑並進行交叉檢驗，以維護分析的完整性；所提出的建議也力求實用，並能在各種組織環境中實施。

全面探討臨床檢驗、互通性和健全的治理將如何決定馬匹醫療保健的未來成功。

總之，在技術進步、護理模式變革以及馬主和臨床醫生日益成長的期望的推動下，馬匹醫療保健產業正經歷著顯著的變革。這些因素為那些具有明確臨床價值、易於融入臨床實踐且擁有穩健供應鏈的解決方案創造了機會。能夠將嚴格的臨床檢驗與切實可行的商業化策略相結合，同時又能應對當地監管和營運現實的機構，將更有可能取得成功。

展望未來，相關人員專注於投資轉化研究、優先考慮診斷和治療互通性，並透過使用者友善平台與馬主互動的利害關係人將獲得競爭優勢。此外，那些透過多元化採購和完善的物流計劃積極應對供應鏈和政策風險的組織，將更有能力在瞬息萬變的貿易環境中維持營運。最終，最具影響力的創新將源於連結研究、臨床實踐和產品開發的合作，從而產生能夠顯著改善馬匹福利和表現的干涉措施。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將穿戴式生物感測器與遠端醫療平台結合，用於持續監測馬匹健康狀況
  • 利用基因組分析進行馬匹疾病預防與治療的精準醫療方法
  • 利用幹細胞和富血小板血漿拓展再生醫學在馬整形外科的應用
  • 開發針對感染疾病感染疾病和通用病威脅的新型馬疫苗
  • 引入數位化記錄和數據分析，以最佳化馬匹的運動表現和福祉。
  • 市場對天然草藥補充劑的需求日益成長，這些補充劑可用於改善馬匹腸道健康和代謝紊亂。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的馬匹保健市場

  • 醫療設備
    • 監測
    • 整形外科
    • 手術器械
  • 診斷試劑
    • 影像診斷
    • 考場
    • 照護端
  • 飼料添加劑
    • 礦物質補充劑
    • 營養補充品
    • 維生素補充劑
  • 製藥
    • 抗發炎藥
      • 皮質類固醇
      • 非類固醇消炎劑
    • 抗寄生蟲藥物
      • 體外寄生蟲殺滅劑
      • 體內殺寄生蟲劑
    • 抗生素
      • BETA-內醯胺類
      • 大環內酯類
      • 四環黴素
    • 荷爾蒙
      • 生長促進劑
      • 生殖
  • 疫苗
    • 失活
    • 活病毒疫苗
    • 重組

9. 按最終用戶分類的馬匹保健市場

  • 馬主
    • 養殖場
    • 個人所有者
  • 網路藥房
    • OTC
    • 處方藥
  • 研究所
    • 私人的
    • 公共
  • 獸醫診所
    • 大型動物醫院
    • 私人診所

10. 按疾病指徵分類的馬匹保健市場

  • 消化系統疾病
    • 絞痛
    • 腹瀉
    • 潰瘍
  • 感染疾病
    • 細菌
    • 寄生
    • 病毒性的
  • 肌肉骨骼疾病
    • 關節疾病
    • 整形外科損傷
    • 軟組織損傷
  • 生殖疾病
    • 子宮內膜炎
    • 不孕症
  • 呼吸系統疾病
    • 下呼吸道
    • 上呼吸道

11. 依給藥途徑分類的馬匹保健市場

  • 吸入
    • 乾粉
    • 霧化
  • 注射
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 口服
    • 液體
    • 粉末
    • 藥片
  • 外用藥物
    • 奶油
    • 凝膠
    • 噴

第12章：各地區的馬匹保健市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按群體分類的馬匹保健市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國馬匹保健市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim GmbH
    • Elanco Animal Health Incorporated
    • Ceva Sante Animale SA
    • Virbac SA
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Bimeda, Inc.
    • Norbrook Laboratories Limited
Product Code: MRR-3F223D52475E

The Equine Healthcare Market is projected to grow by USD 5.83 billion at a CAGR of 6.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.46 billion
Estimated Year [2025] USD 3.70 billion
Forecast Year [2032] USD 5.83 billion
CAGR (%) 6.73%

An authoritative framing of contemporary equine healthcare priorities emphasizing prevention, diagnostic integration, and collaborative clinical innovation

The equine healthcare landscape is at an inflection point where clinical imperatives, owner expectations, and technological capabilities converge to reshape priorities across care delivery and product development. Prevention and wellness are increasingly central, with growing emphasis on diagnostics that enable early detection and on therapeutics that support long-term performance and quality of life. As a result, stakeholders from clinicians to owners are adapting practices and procurement strategies to reflect a more proactive model of equine health management.

Transitioning from a reactive model toward preventive care requires new workflows, investments in monitoring and diagnostics, and greater collaboration between veterinary practitioners, research laboratories, and product developers. These shifts are driven by rising expectations for outcomes, the need for evidence-based interventions, and the broader availability of digital tools that permit remote monitoring and data-driven decision-making. Consequently, organizations operating within this space must reconcile traditional clinical approaches with innovations that promise improved detection, targeted therapies, and measurable welfare gains.

Given these dynamics, the opening of any strategic initiative should emphasize alignment across clinical, commercial, and owner constituencies. Clarity of purpose, coupled with pragmatic pathways for piloting and scaling new technologies, will determine which innovations achieve traction. Ultimately, the equine healthcare sector is moving toward a more integrated, data-informed paradigm that rewards collaboration, rigorous validation, and a clear orientation toward long-term animal welfare.

How technological advances, shifting care delivery models, and owner expectations are coalescing to redefine equine healthcare delivery and product innovation

The equine healthcare environment is experiencing transformative shifts driven by technological maturation, evolving disease management philosophies, and changes in stakeholder behavior. Advanced imaging and point-of-care diagnostics are reducing diagnostic uncertainty and shortening time to intervention, while wearable monitoring platforms are enabling continuous data capture that supports individualized care plans. At the same time, therapeutics are diversifying with targeted pharmaceuticals and specialized feed supplements designed to support recovery and performance, thereby broadening treatment pathways available to clinicians and owners alike.

Concurrently, veterinary practices are adapting to new revenue and care models that emphasize telemedicine, remote monitoring, and subscription-based wellness programs. These operational shifts are accompanied by enhanced expectations from owners for transparency, convenience, and measurable outcomes, which in turn accelerate adoption of services that deliver real-time insights and demonstrable benefits. Research laboratories are responding by prioritizing translational studies that validate diagnostic tools and therapeutic regimens, creating a feedback loop between clinical practice and scientific investigation.

Moreover, regulatory thinking and supply chain resilience are influencing product strategies, prompting manufacturers to invest in formulation stability, cold-chain logistics, and simplified administration routes. Taken together, these trends are not isolated; rather, they reinforce one another to create a more interconnected and agile ecosystem where innovations that demonstrate value and ease of use are most likely to scale.

Assessing the operational and supply chain consequences of recent trade policy shifts that are reshaping procurement, sourcing, and logistics priorities across equine healthcare

Recent tariff changes in the United States have introduced a layer of complexity that affects supply chains, sourcing strategies, and product lifecycle planning across the equine healthcare sector. Increased duties on imported components and finished products have prompted manufacturers and distributors to reassess supplier relationships, prioritize local sourcing where feasible, and reconfigure logistics to preserve margin and continuity of supply. These adjustments have practical implications for the availability, lead times, and cost structure of devices, diagnostics, and select pharmaceutical products.

In response, many stakeholders have pursued diversification strategies to mitigate exposure to single-source dependencies. Manufacturers are exploring alternative manufacturing bases and dual-sourcing arrangements, while distributors and large veterinary practices are intensifying inventory planning and safety stock policies to offset lead-time volatility. At the same time, contract manufacturers and domestic suppliers are experiencing increased interest from clients seeking reliable alternatives to cross-border shipments, which reshapes negotiation dynamics and capacity planning within the industry.

Regulatory compliance and labeling requirements have also become more salient in procurement decisions, as products that must transit complex customs regimes can face additional scrutiny and delay. Consequently, procurement teams are allocating more resources to customs expertise and supplier qualification, while research laboratories and clinicians are prioritizing products whose supply chains offer demonstrable resilience. The combined effect is a market that values transparency, redundancy, and flexibility in the face of evolving trade policies.

Comprehensive segmentation analysis mapping product types, end users, disease indications, and administration routes to strategic innovation and commercial pathways

An effective segmentation framework reveals where innovation and demand intersect across product types, end users, disease indications, and routes of administration, providing a roadmap for targeted development and commercialization. When exploring product type, the landscape encompasses devices, diagnostics, feed supplements, pharmaceuticals, and vaccines. Within devices there are opportunities in monitoring devices that support continuous assessment, orthopedic instruments that address bone and joint conditions, and surgical instruments that enable advanced interventions. Diagnostics span imaging modalities, laboratory-based assays, and point-of-care technologies that bring faster decision-making into clinical contexts. Feed supplements divide into mineral, nutritional, and vitamin formulations that support systemic health and recovery. Pharmaceuticals include anti-inflammatories, anti-parasitic agents, antibiotics, and hormones; within anti-inflammatories the categories of corticosteroids and nonsteroidal anti-inflammatory drugs shape therapeutic choice, while anti-parasitic solutions encompass ectoparasiticides and endoparasiticides. Antibiotic classes relevant to equine care include beta lactams, macrolides, and tetracyclines, and hormones are differentiated by growth- versus reproductive-focused agents. Vaccines are offered in inactivated, live attenuated, and recombinant formats, each with distinct storage and administration considerations.

From an end user perspective, the ecosystem includes equine owners, online pharmacies, research laboratories, and veterinary practices. Equine owners are comprised of breeding farms and individual owners who have differing priorities around management scale and investment in preventive care. Online pharmacies operate across over-the-counter and prescription channels, providing convenience and range but requiring careful clinical oversight. Research laboratories are characterized by private and public institutions that drive innovation and validation, whereas veterinary practices range from large animal hospitals with integrated services to private practices focused on personalized care. Disease indication segmentation likewise highlights areas of clinical need and product alignment: digestive disorders such as colic, diarrhea, and ulcers demand rapid diagnostic and supportive care; infectious diseases categorized as bacterial, parasitic, and viral require integrated prevention and treatment strategies; musculoskeletal disorders covering joint disorders, orthopedic injuries, and soft tissue injuries benefit from combined rehabilitative and pharmaceutical approaches; reproductive disorders including endometritis and infertility intersect with both therapeutic and diagnostic solutions; respiratory disorders divided into lower and upper respiratory conditions necessitate specific administration routes and supportive care plans.

Considering route of administration clarifies development and adoption dynamics across inhalation, injectable, oral, and topical options. Inhalation approaches include dry powder delivery and nebulization, both suited for targeted respiratory interventions. Injectable formats encompass intramuscular, intravenous, and subcutaneous routes that influence onset and dosing strategies. Oral delivery consists of liquids, powders, and tablets that prioritize ease of administration for at-home care scenarios. Topical therapies in creams, gels, and sprays enable localized treatment with minimal systemic exposure. By mapping these segmentation dimensions together, developers and clinicians can better prioritize investments and tailor offerings to the specific needs and constraints of each user group and indication.

Regional differentiation and strategic opportunities across the Americas, Europe Middle East and Africa, and Asia Pacific that inform go to market and R D prioritization

Regional dynamics shape where investment, research emphasis, and adoption are most pronounced, and understanding these differences is essential for market entry and partnership decisions. In the Americas, a combination of advanced clinical infrastructure, strong owner engagement, and a thriving companion and performance equine culture drives demand for diagnostic sophistication, specialized therapeutics, and integrated care models. This region prioritizes high-evidence interventions and shows early adoption for remote monitoring and telehealth-enabled services, which supports a premiumization of care in certain segments.

Within the Europe, Middle East & Africa cluster, variability is pronounced across regulatory environments and veterinary practice norms, yet there is consistent momentum toward harmonized standards of care, particularly for infectious disease surveillance and vaccination strategies. Public-private collaboration and strong research networks in parts of this region are facilitating multicenter studies and translational research, while some markets emphasize cost-effective formulations and pragmatic protocols suited to diverse practice settings.

Asia-Pacific presents a mix of rapid clinical modernization, expanding middle-class ownership of performance and leisure horses, and an increasing focus on local manufacturing capability. In this region, demand growth is often accompanied by targeted investments in domestic research and production, and regulatory pathways continue to evolve to accommodate a broader array of diagnostics and therapeutics. Taken together, each geographic cluster offers distinct opportunities and constraints, so prioritizing regional strategies that account for clinical practice patterns, regulatory frameworks, and local supply chain realities will yield the most sustainable outcomes.

An assessment of competitive dynamics emphasizing evidence generation, supply chain agility, and strategic partnerships that drive differentiation and adoption

Competitive dynamics in equine healthcare are defined by a mix of established animal health manufacturers, specialist device and diagnostics firms, veterinary distribution networks, and agile start-ups focused on niche therapeutics or digital monitoring. Established players tend to leverage scale, regulatory experience, and broad distribution to maintain presence across multiple product categories, while specialist firms compete on deep clinical expertise, targeted technology platforms, and close alignment with veterinary practitioners. New entrants bring disruptive potential through digital tools, point-of-care diagnostics, and formulation innovations that lower barriers to use and enhance owner engagement.

Partnerships between device makers and diagnostic developers are increasingly common, enabling integrated solutions that combine monitoring, data analytics, and therapeutic recommendations. Additionally, collaborations between research laboratories and industry are accelerating translational work that validates new interventions under clinical conditions. Distribution channels also matter: online pharmacies and specialized veterinary distributors influence product visibility and access, while large animal hospitals and private practices shape clinical adoption based on real-world performance and ease of integration into care pathways.

Intellectual property, regulatory experience, and manufacturing agility are differentiators that influence competitive positioning. Firms that can demonstrate clinical outcomes, streamline administration, and provide robust support for practitioners will be better positioned to capture preference. Ultimately, company strategies that emphasize evidence generation, supply chain reliability, and tailored commercial engagement are most likely to succeed in a complex and clinically driven market.

Practical strategic initiatives for industry leaders to strengthen resilience, validate innovations clinically, and accelerate adoption through integrated commercial approaches

Industry leaders should prioritize a set of actionable initiatives that balance near-term operational resilience with longer-term innovation and evidence development. First, invest in supply chain transparency and redundancy to mitigate the operational impacts of trade policy shifts and component scarcity. By fostering relationships with multiple qualified suppliers and strengthening logistics planning, organizations can reduce disruption risk while maintaining quality standards.

Second, accelerate clinical validation programs that pair diagnostics with therapeutics to demonstrate real-world outcomes. Rigorous, translational studies that engage veterinary practices and research laboratories will unlock practitioner confidence and facilitate broader adoption. Third, embrace digital integration by deploying monitoring platforms and telemedicine workflows that improve continuity of care and create value through data-driven insights. These tools should be designed for ease of use and seamless integration into existing clinical systems.

Fourth, tailor commercial approaches to end-user segments by recognizing differences between breeding farms and individual owners, and by developing route-of-administration strategies that prioritize adherence and practicality. Fifth, explore strategic alliances that combine complementary strengths across device, diagnostic, and pharmaceutical domains to deliver bundled offerings aligned with clinical pathways. Finally, commit to regulatory and compliance excellence to expedite approvals and ensure consistent market access. Together, these actions provide a pragmatic roadmap for advancing both business resilience and clinical impact.

A rigorous multi-method research framework combining primary stakeholder insights, regulatory review, and cross segmentation analysis to support actionable conclusions

The research underpinning this report synthesizes multiple qualitative and quantitative approaches to ensure robust, actionable findings. Primary research included structured interviews with veterinary practitioners, laboratory scientists, industry executives, and equine owners to capture diverse perspectives on clinical needs, adoption barriers, and product performance. Secondary research involved a careful review of peer-reviewed literature, regulatory guidance, technical standards, and public policy documents to ground observations in validated sources and to contextualize regional differences.

Analytical methods incorporated cross-segmentation mapping to identify where product types, end users, disease indications, and routes of administration intersect with unmet needs. Supply chain and trade policy analyses were conducted using customs data, logistics performance indicators, and public trade notices to assess operational vulnerabilities. Competitive landscape analysis combined patent filings, product registries, and clinical trial registries to evaluate innovation trajectories and differentiation strategies. Throughout the study, methods emphasized triangulation of evidence, iterative validation with subject-matter experts, and sensitivity to regional regulatory and practice variations.

This layered methodology ensures conclusions are grounded in observed practice and documented evidence while remaining sensitive to emerging trends. Where primary data were limited, findings were qualified and cross-checked to preserve analytic integrity, and recommendations were formulated to be pragmatic and implementable across a range of organizational contexts.

Synthesis and forward looking perspective on how clinical validation, interoperability, and resilient operations will determine future success in equine healthcare

In closing, the equine healthcare sector is undergoing meaningful evolution driven by technological advances, shifting care models, and heightened expectations from owners and clinicians. These forces are creating opportunities for solutions that deliver clear clinical value, are easy to integrate into practice, and exhibit resilient supply chains. Success will favor organizations that can marry rigorous clinical validation with pragmatic commercialization strategies, while also demonstrating responsiveness to regional regulatory and operational realities.

Going forward, stakeholders who invest in translational research, prioritize interoperability between diagnostics and therapeutics, and engage owners through user-friendly platforms will secure competitive advantage. Moreover, those who proactively address supply chain and policy risks through diversified sourcing and robust logistics planning will be better equipped to sustain operations in a fluid trade environment. Ultimately, the most impactful advances will emerge from collaborations that bridge research, clinical practice, and product development, producing interventions that meaningfully enhance equine welfare and performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of wearable biosensors and telehealth platforms for continuous equine health monitoring
  • 5.2. Precision medicine approaches using genomic profiling for equine disease prevention and treatment
  • 5.3. Expansion of regenerative therapies using stem cells and platelet rich plasma in equine orthopedics
  • 5.4. Development of novel equine vaccines targeting emerging infectious diseases and zoonotic threats
  • 5.5. Adoption of digital recordkeeping and data analytics for optimizing equine performance and welfare
  • 5.6. Rising demand for natural and herbal supplements addressing equine gut health and metabolic disorders

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Equine Healthcare Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Monitoring
    • 8.1.2. Orthopedic
    • 8.1.3. Surgical Instruments
  • 8.2. Diagnostics
    • 8.2.1. Imaging
    • 8.2.2. Laboratory
    • 8.2.3. Point Of Care
  • 8.3. Feed Supplements
    • 8.3.1. Mineral Supplements
    • 8.3.2. Nutritional Supplements
    • 8.3.3. Vitamin Supplements
  • 8.4. Pharmaceuticals
    • 8.4.1. Anti-Inflammatories
      • 8.4.1.1. Corticosteroids
      • 8.4.1.2. NSAIDs
    • 8.4.2. Anti-Parasitic
      • 8.4.2.1. Ectoparasiticides
      • 8.4.2.2. Endoparasiticides
    • 8.4.3. Antibiotics
      • 8.4.3.1. Beta Lactams
      • 8.4.3.2. Macrolides
      • 8.4.3.3. Tetracyclines
    • 8.4.4. Hormones
      • 8.4.4.1. Growth
      • 8.4.4.2. Reproductive
  • 8.5. Vaccines
    • 8.5.1. Inactivated
    • 8.5.2. Live Attenuated
    • 8.5.3. Recombinant

9. Equine Healthcare Market, by End User

  • 9.1. Equine Owners
    • 9.1.1. Breeding Farms
    • 9.1.2. Individual Owners
  • 9.2. Online Pharmacies
    • 9.2.1. OTC
    • 9.2.2. Prescription
  • 9.3. Research Laboratories
    • 9.3.1. Private
    • 9.3.2. Public
  • 9.4. Veterinary Practices
    • 9.4.1. Large Animal Hospitals
    • 9.4.2. Private Practices

10. Equine Healthcare Market, by Disease Indication

  • 10.1. Digestive Disorders
    • 10.1.1. Colic
    • 10.1.2. Diarrhea
    • 10.1.3. Ulcers
  • 10.2. Infectious Diseases
    • 10.2.1. Bacterial
    • 10.2.2. Parasitic
    • 10.2.3. Viral
  • 10.3. Musculoskeletal Disorders
    • 10.3.1. Joint Disorders
    • 10.3.2. Orthopedic Injuries
    • 10.3.3. Soft Tissue Injuries
  • 10.4. Reproductive Disorders
    • 10.4.1. Endometritis
    • 10.4.2. Infertility
  • 10.5. Respiratory Disorders
    • 10.5.1. Lower Respiratory
    • 10.5.2. Upper Respiratory

11. Equine Healthcare Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Dry Powder
    • 11.1.2. Nebulization
  • 11.2. Injectable
    • 11.2.1. Intramuscular
    • 11.2.2. Intravenous
    • 11.2.3. Subcutaneous
  • 11.3. Oral
    • 11.3.1. Liquids
    • 11.3.2. Powders
    • 11.3.3. Tablets
  • 11.4. Topical
    • 11.4.1. Creams
    • 11.4.2. Gels
    • 11.4.3. Sprays

12. Equine Healthcare Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Equine Healthcare Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Equine Healthcare Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. Boehringer Ingelheim GmbH
    • 15.3.4. Elanco Animal Health Incorporated
    • 15.3.5. Ceva Sante Animale S.A.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Vetoquinol S.A.
    • 15.3.8. Dechra Pharmaceuticals PLC
    • 15.3.9. Bimeda, Inc.
    • 15.3.10. Norbrook Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA EQUINE HEALTHCARE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. EQUINE HEALTHCARE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. EQUINE HEALTHCARE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. EQUINE HEALTHCARE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 325. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 326. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 327. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. GLOBAL EQUINE HEALTHCARE M